Skip to content
← Full study record

NCT01183780 · MORE INFO

Limitations, agreements, and source contact

A Study in Second Line Metastatic Colorectal Cancer · Source last updated 2019-09-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer
Complete source fields
certain Agreement
other Details
Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice